---
schema_version: "secwatch.filing_event.v1"
accession: "0001108205-23-000048"
form_type: "8-K"
ticker: "CRIS"
cik: "0001108205"
company_name: "CURIS INC"
filed_at: "2023-05-04T23:59:59+00:00"
generated_at: "2026-06-15T19:52:13.785460+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Curis Q1 net loss narrows to $11.6M; enrolls 9 patients for emavusertib; new CDO

## Summary
- Net loss $11.6M ($0.12/share) vs $16.1M ($0.18) YoY; revenue $2.3M, up from $2.1M.
- Enrolled 9 additional patients at 200mg BID for emavusertib; FDA partial clinical hold discussion expected in Q3 2023.
- Appointed Jonathan Zung, Ph.D. as Chief Development Officer effective May 1, 2023; previously CDO at Evelo.
- Cash and investments $71.8M as of Dec 31, 2022; cash runway expected into 2025.
- R&D expenses down to $9.1M from $11.4M; G&A down to $4.8M from $5.7M.

## SEC filing metadata
- accession: 0001108205-23-000048
- form_type: 8-K
- ticker: CRIS
- cik: 0001108205
- company_name: CURIS INC
- filed_at: 2023-05-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000048/0001108205-23-000048-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000048/cris-20230504.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001108205-23-000048
- JSON: https://secwatch.observer/filing/0001108205-23-000048.json
- Plain text: https://secwatch.observer/filing/0001108205-23-000048.txt

## Key facts
- Earnings Releases
  CURIS INC reported the first quarter ended March 31, 2023 results: revenue $2.3 million, net income a net loss of $11.6 million, EPS $0.12 per share on both a basic and diluted basis.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $2.3 million
  - Net income: a net loss of $11.6 million
  - EPS: $0.12 per share on both a basic and diluted basis
  - Result: reported results
  source text: and diluted basis as compared to $16.1 million or $0.18 per share on both a basic and diluted basis, for the same period in 2022. Revenues for the first quarter of 2023 were $2.3 million as compared to $2.1 million for the same period in 2022. Revenues for both periods consist of royalty revenues from Genentech's and Roche's sales of Erivedge®. Research and
  evidence_url: https://www.sec.gov/Archives/edgar/data/1108205/000110820523000048/0001108205-23-000048-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.